Gastric Cancer

Cancer Screening: Theory and Practice

Volumn , Issue , 2021, Pages 515-529

  Parkin, D Maxwell ^a   Pisani, Paola ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000165010     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429179587-22     Document Type: Chapter

References (63)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54:594-606.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention, and projections of future burden. Int J Cancer 1993; 55:891-903.
3. Kosary CL, Gloeckler Ries LA, Miller BA, Hankey BF, Harras A, Edwards BK, eds. SEER Cancer Statistics Review, 1973-92 Tables and Graphs. Bethesda, MD, National Institutes of Health, 1995.
4. Berrino F, Sant M, Verdecchia R, Capocaccia T, Hakulinen T, Esteve J. Survival of Cancer Patients in Europe: The EUROCARE Study (IARC Publication No. 132). Lyon, International Agency for Research on Cancer, 1995.
5. Sankaranarayanan R, Swaminathan R, Black RJ. Global variations in Cancer survival. Cancer 1996; 78:2461-2464.
6. Hanai A, Tsukuma H, Hiyama T, Fujimoto I. Cancer survival in Osak. In: Tominga S, et al, eds. Cancer Mortality and Morbidity Statistics. Japan and the World 1994. GANN Monograph on Cancer Research 1994; 41:159-165.
7. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. Lyon, International Agency for Research on Cancer, 1993.
8. Correa P, Chen VW. Gastric cancer. Cancer Surv 1994; 19-20:55-76.
9. Hanai A, Fujimoto I, Taniguchi H. Trends of stomach cancer incidence and histological types in Osaka. In: Magnus K, ed. Trends in Cancer Incidence. New York: McGraw Hill 1982:143-154.
10. Lundergardh G, Lindgren A, Rohul A, Nyren O, Hensson LE, Bergstrom R, Adami HO. Intestinal and diffuse types of gastric cancer: secular trends in Sweden since 1951. Br J Cancer 1991; 64:1182-1186.
11. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B. Gastric precancerous process in a high risk population: cohort follow-up. Can Res 1990; 50:4737-4740.
12. Inoue M, Tajima K, Kobayashi S, Suzuki T, Matsuura A, Nakamura T, Shirai M, Nakamura S, Inuzuka K, Tominaga S. Protective factor against progression from atrophic gastritis to gastric cancer-data from a cohort study in Japan. Int J Cancer 1996; 66:309-314.
13. Sipponen P, Riihela M, Hyvarinen H, Seppala K. Chronic nonatrophic (‘superficial’) gastritis increases the risk of gastric carcinoma. Scand J Gastroenterol 1994; 29:336-340.
14. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52:6735-6740.
15. Kodama M, Kodama T, Suzuki H, Kondo K. Effect of rice and salty rice diet on the structure of mouse stomach. Nutr Cancer 1984; 6:135-147.
16. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 61. Lyon, International Agency for Research on Cancer, 1994.
17. Sobala GM Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. Gastroenterology 1989; 97:357-363.
18. Sakaki N, Momma K, Egawa N, Yamada Y, Kan T, Ishiwata J. The influence of Helicobacter pylori infection on the progression of gastric mucosal atrophy and occurrence of gastric cancer. Eur J Gastroenterol Hepatol 1995; 7:S59-S62.
19. Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267:1655-1658.
20. Kuipers EJ, Perez-Perez GI, Meuwissen SGM, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the CagA status. J Natl Cancer Inst 1995; 87:1777-1780.
21. Tsukuma H, Mishima T, Oshima A. Prospective study of “early” gastric cancer. Int J Cancer 1983; 31:421-426.
22. Hakkinen IPT. An immunochemical method for detecting carcinomatous secretion from human gastric juice. Scand J Gastroenterol 1966; 1:28-32.
23. Hakama M, Pukkala E. Evaluation of an immunological screening for stomach cancer. In: Chamberlain J, Miller AB eds. Screening for Gastric Cancer. Toronto: Hans Huber Publishers, 1988:71-75.
24. Hakama M, Stenman UH, Knekt P, Jarvisalo J, Leion A, Hakulinen T, Maatela J, Aromaa A. Tumour markers and screening for gastrointestinal cancer: a follow up study in Finland. J Med Screen 1994; 1:60-64.
25. Hisamichi S, Sugawara N. Mass screening for gastric cancer by X-ray examination. Jpn J Clin Oncol 1984; 14:211-223.
26. Oshima A. Screening for stomach cancer: the Japanese program. In: Chamberlain J, Miller AB, eds. Screening for Gastrointestinal Cancer. Toronto: Hans Huber Publishers, 1988:65-70.
27. Yamagata S, Sugawara N, Hisamichi S. Mass screening for cancer in Japan-present and future. In: Yamagata S, Hirayama T, Hisamichi S, eds. Recent Advances in Cancer Control (Proceedings of 6th Asia Pacific Cancer Conference). Amsterdam: Excerpta Medica, 1983.
28. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, Yamazaki H, Oshima A. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990; 65:1255-1260.
29. Samloff IM. Pepsinogens, pepsins and pepsin inhibitors. Gastroenterology 1971; 60:586-604.
30. Samloff IM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1982; 82:26-33.
31. Samloff IM, Secrist DM, Passaro E. A study of the relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology 1975; 69:1196-1200.
32. Samloff IM, Varis K, Ibamaki T, Sicerala M, Rotter JI. Relationships among serum pepsinogen 1, serum pepsinogen 11 and gastric mucosal histology: a study in relatives of patients with pernicious anemia, Gastroenterology 1982; 83:204-209.
33. Westerveid BD, Pals G, Lamers CBHW, Defize J, Pronk JC, Frants RR, Ooms ECM, Kreuning J, Kostense PJ, Eriksson AW, Meuwissen SGM. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987; 59:952-958.
34. Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T, Takahashi K. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987; 22:133-141.
35. Nomura AMY, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med 1980; 93:537-540.
36. Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 1993; 2:461-466.
37. Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Harkonen M, Hakama MK. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996; 144:142-149.
38. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-1305.
39. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
40. Nomura A, Stemmermann GN, Chyou PH, Kato I, Pérez-Pérez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325:1132-1136.
41. Lin JT, Wang LY, Wang JT, Wang TH, Yang CS, Chen CJ. Weak association between Helicobacter pylori infection and gastric cancer risk: epidemiologic evidence from Taiwan. Gastroenterology 1993; 107:A421.
42. Webb PM, Yu MC, Forman D, Henderson BE, Newell DG, Yuan JM, Gao YT, Ross RK. An apparent lack of association between Helicobacter pylori infection and risk of gastric cancer in China. Int J Cancer 1996; 67:603-607.
43. Stemmermann GN, Samloff IM, Normura AMY, Heilbrun LK. Serum pepsinogens I and II and stomach cancer. Clin Chim Acta 1987; 163:191-198.
44. Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, Tsukuda S, Kido M, Ishihama S, Shimizu Y, Suzuki T, Kurchkawa K. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84:1086-1090.
45. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995; 86:1210-1215.
46. Forman D, Webb P, Parsonnet J. Helicobacter and gastric cancer. Lancet 1994; 343:243-244.
47. Parsonnet J, Harris RA, Hack HW, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348:150-154.
48. Hisamichi S, Fukao A, Sugawara N, Nishikouri M, Komatsu S, Tsuji I, Tsubono Y, Takano A. Evaluation of mass screening programme for stomach cancer in Japan. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge: Cambridge University Press, 1991:357-370.
49. Oshima A, Hanai A, Fujimoto I. Evaluation of a mass screening program for stomach cancer. NCI Monogr 1979; 53:181-186.
50. Fukao A, Hisamichi S, Komatsu S, Shimizu H, Satoh H, Nakatsuka H, Watanabe T, Fujisaku S, Ichinowatari Y, Kuroda S, Ida Y, Suda S, Kato K, Ikeda M. Comparison of characteristics between frequent participants and non-participants in screening program for stomach cancer. Tohoku J Exp Med 1992; 166:459-469.
51. Oshima A, Hirata N, Ubukata T, Umeda K, Fujimoto I. Evaluation of a mass screening program for stomach cancer with a case-control study design. Int J Cancer 1986; 38:829-833.
52. Fukao A, Hisamichi S, Sugawara N. A case-control study on evaluating the effect of mass screening on decreasing advanced stomach cancer. J Gastroenterol Mass Survey, 1987; 75:112-116 (in Japanese).
53. Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi prefecture, Japan: a population-based case-control study. Int J Cancer 1995; 60:45-48.
54. Pisani P, Oliver WE, Parkin DM, Alvarez N, Vivas J. Case-control study of gastric cancer screening in Venezuela. Br J Cancer 1994; 69:1102-1105.
55. Kuroishi T, Hirose K, Tajima K, Tominaga S. Cancer mortality in Japan (1950-1990). GANN Monogr Cancer Res 1994; 41:1-105.
56. Kuroishi T, Hirose K, Nakagawa N, Tominaga S. Comparison of time trends of stomach cancer death rates between the model area of the screening program and the control area. J Gastroenterol Mass Survey 1983; 58:45-52 (in Japanese).
57. Fukao A, Hisamichi S, Kamatsu S, Sugawara N, Takano A. Risk of leukaemia among participants of gastric mass screening survey in Japan: a population-based case control study. Cancer Detect Prevent 1992; 16:283-286.
58. Davis RE, Graham DY. Endoscopic complications. Gastrointest Endosc 1979; 25:146-149.
59. Schuller KFR, Cotton PB, Salmon PR. The hazards of digestive fiberendoscopy: a study of British experience. Gut 1972; 13:1027-1032.
60. Tsuji I, Fukao A, Sugawara N, Shoji T, Kuwajima I, Hisamichi S. Cost-effectiveness analysis of screening for gastric cancer in Japan. Tohoku J Exp Med 1991; 164:279-284.
61. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
62. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
63. Chamberlain J, Day NE, Hakama M, Miller AB, Prorok PC. UICC workshop of the Project on Evaluation of Screening Programmes for Gastrointestinal Cancer. Int J Cancer 1986; 37:329-334.